Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
10:45am, Sunday, 18'th Aug 2024
Despite DexCom's recent challenges, it still has ample growth opportunities. Novartis is a reliable dividend payer that recently changed its business for the better.
Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?
11:20am, Thursday, 15'th Aug 2024
Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.
Novartis loses initial bid to block generic of best-selling heart drug
03:58pm, Monday, 12'th Aug 2024
Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a
10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next
07:00am, Saturday, 10'th Aug 2024
Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the
Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. pla
Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a
US FDA approves Novartis' kidney disease drug
02:23pm, Wednesday, 07'th Aug 2024
The U.S. Food and Drug Administration has approved the use of Novartis' drug to treat patients with a type of kidney disease, the health regulator's website showed on Wednesday.
Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims
04:43pm, Monday, 05'th Aug 2024
Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and devel
Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer
08:02am, Wednesday, 24'th Jul 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer.
Novartis: Another Beat, Another Raise
03:50am, Saturday, 20'th Jul 2024
The company continues to deliver strong turnover growth and core margin expansion. Ongoing buyback combined with a juicy dividend yield provides downside protection. Positive contributions from newer
Why Novartis Deserves Your Attention After Q2 2024 Results
10:15am, Friday, 19'th Jul 2024
On July 18, Novartis AG released its second-quarter 2024 financial results, which were solid. The company's free cash flow was about $4.62 billion for the second quarter of 2024, up 40% year over year
Pharma Leader Beats on Earnings, But Shares Fall
08:55am, Friday, 19'th Jul 2024
Novartis NYSE: NVS is the seventh largest pharmaceutical company in the world, and is based in Switzerland. The firm reported Q2 2024 financial results on Jul. 18, 2024.
Novartis expects 'strong momentum' going into second half, says CEO Vasant Narasimhan
06:23pm, Thursday, 18'th Jul 2024
Vasant Narasimhan, Novartis CEO, joins CNBC's Angelica Peebles on 'The Exchange' to discuss Q2 earnings, reception of its prostate cancer drug, and more.
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
02:15pm, Thursday, 18'th Jul 2024
Drugmaker Novartis' second-quarter results were better than expected. Profit guidance for the remainder of the year was also raised.
Novartis Falls Despite Earnings Beat, Guidance Raise
10:51am, Thursday, 18'th Jul 2024
Novartis (NVS) American depositary receipts (ADRs) slipped Thursday even though the pharmaceutical giant beat second-quarter earnings expectations and raised its full-year core operating income guidan
